TMLRpred: A machine learning classification model to distinguish reversible EGFR double mutant inhibitors.

Abstract excerpt

The EGFR is a clinically important therapeutic drug target in lung cancer. The first-generation tyrosine kinase inhibitors used in clinics are effective against L858R-mutated EGFR. However, relapse of the disease due to the presence of resistant mutation (T790M) makes these inhibitors ineffective. This has necessitated the need to identify new potent EGFR inhibitors against the resistant double mutants....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Datasets as Topic
• Share to ErbB Receptors
• Share to Machine Learning